[go: up one dir, main page]

MA46866A - Une forme cristalline d'un inhibiteur de magl - Google Patents

Une forme cristalline d'un inhibiteur de magl

Info

Publication number
MA46866A
MA46866A MA046866A MA46866A MA46866A MA 46866 A MA46866 A MA 46866A MA 046866 A MA046866 A MA 046866A MA 46866 A MA46866 A MA 46866A MA 46866 A MA46866 A MA 46866A
Authority
MA
Morocco
Prior art keywords
crystalline form
magl inhibitor
magl
inhibitor
crystalline
Prior art date
Application number
MA046866A
Other languages
English (en)
Other versions
MA46866B1 (fr
Inventor
Channing Rodney Beals
Jacqueline Lorayne Blankman
Cheryl A Grice
Kurt G Grimm
Todd K Jones
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA46866A publication Critical patent/MA46866A/fr
Publication of MA46866B1 publication Critical patent/MA46866B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA46866A 2016-11-16 2017-11-15 Une forme cristalline d'un inhibiteur de magl MA46866B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423126P 2016-11-16 2016-11-16
PCT/US2017/061875 WO2018093953A1 (fr) 2016-11-16 2017-11-15 Formes cristallines d'un inhibiteur de magl

Publications (2)

Publication Number Publication Date
MA46866A true MA46866A (fr) 2021-06-02
MA46866B1 MA46866B1 (fr) 2021-11-30

Family

ID=62145805

Family Applications (2)

Application Number Title Priority Date Filing Date
MA46866A MA46866B1 (fr) 2016-11-16 2017-11-15 Une forme cristalline d'un inhibiteur de magl
MA58133A MA58133B1 (fr) 2016-11-16 2017-11-15 Une forme cristalline d'un inhibiteur de magl

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA58133A MA58133B1 (fr) 2016-11-16 2017-11-15 Une forme cristalline d'un inhibiteur de magl

Country Status (38)

Country Link
US (2) US11142517B2 (fr)
EP (2) EP3541807B1 (fr)
JP (2) JP7042548B2 (fr)
KR (1) KR102508739B1 (fr)
CN (2) CN110291083B (fr)
AU (1) AU2017361257B2 (fr)
BR (1) BR112019010003A2 (fr)
CA (1) CA3043610A1 (fr)
CL (1) CL2019001340A1 (fr)
CO (1) CO2019005045A2 (fr)
CR (1) CR20190242A (fr)
CY (1) CY1124870T1 (fr)
DK (1) DK3541807T3 (fr)
DO (1) DOP2019000120A (fr)
EA (1) EA201991086A1 (fr)
EC (1) ECSP19035171A (fr)
ES (2) ES2966939T3 (fr)
GE (1) GEP20237559B (fr)
HR (2) HRP20211863T1 (fr)
HU (2) HUE064559T2 (fr)
IL (1) IL266548A (fr)
JO (1) JOP20190109B1 (fr)
LT (1) LT3541807T (fr)
MA (2) MA46866B1 (fr)
MX (2) MX2019005767A (fr)
MY (1) MY199386A (fr)
NI (1) NI201900053A (fr)
PE (1) PE20191239A1 (fr)
PH (1) PH12019501068A1 (fr)
PL (2) PL3964503T3 (fr)
PT (1) PT3541807T (fr)
RS (2) RS65016B1 (fr)
SI (1) SI3541807T1 (fr)
SM (2) SMT202100675T1 (fr)
TN (1) TN2019000151A1 (fr)
UA (1) UA124585C2 (fr)
WO (1) WO2018093953A1 (fr)
ZA (1) ZA201903093B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049690T2 (hu) 2012-01-06 2020-10-28 Lundbeck La Jolla Research Center Inc Karbamátvegyületek és eljárások azok elõállítására és alkalmazására
KR20180004263A (ko) 2015-05-11 2018-01-10 어바이드 테라퓨틱스, 인크. 염증 또는 신경병성 통증의 치료 방법
EP3515897B1 (fr) 2016-09-19 2021-08-18 H. Lundbeck A/S Carbamates de pipérazine comme modulateurs de magl et/ou de abhd6 et leur utilisation
WO2018093950A1 (fr) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Formulations pharmaceutiques
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
HRP20211863T1 (hr) 2016-11-16 2022-03-04 H. Lundbeck A/S Formulacija za kontinuirano otpuštanje kolhicina i postupci priprave istog
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
SI3630744T1 (sl) 2017-05-23 2023-04-28 H. Lundbeck A/S Pirazolni MAGL-inhibitorji
EA202090312A1 (ru) 2017-08-29 2020-08-05 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Спироциклические соединения и способы их получения и применения
EP3793547A4 (fr) 2018-05-15 2021-11-17 H. Lundbeck A/S Inhibiteurs de magl
WO2020016710A1 (fr) * 2018-07-19 2020-01-23 Pfizer Inc. Composés spiro hétérocycliques utilisés en tant qu'inhibiteurs de magl
BR112021013917A2 (pt) * 2019-11-15 2022-05-24 H Lundbeck As Forma cristalina de um inibidor de magl, composição farmacêutica e uso
KR20230004622A (ko) 2020-04-21 2023-01-06 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제의 합성
WO2023092079A1 (fr) * 2021-11-19 2023-05-25 Bryant Cynthia W Utilisation de composés cannabinoïdes pour traiter des troubles gastro-intestinaux
CN117665187B (zh) * 2023-11-23 2024-08-16 宁波大红鹰药业股份有限公司 一种舒林酸中间体杂质的测定方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
ATE195075T1 (de) 1991-11-22 2000-08-15 Procter & Gamble Pharma Risedronat enthaltende arzneimittel mit verzögerter wirkstoffabgabe
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
CA2147283C (fr) 1992-10-16 2007-01-16 Kouichi Nakamichi Methode de fabrication de matrices de cire
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
BR0017386A (pt) 2000-12-18 2004-01-13 Novartis Ag Combinação terapêutica de amlodipina e benazepril
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ATE420644T1 (de) 2002-02-20 2009-01-15 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
AU2006218193A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
CA2631233C (fr) 2005-11-28 2011-11-08 Marinus Pharmaceuticals Formes galeniques de ganaxolone et procedes de preparation et d'utilisation de celles-ci
EP1938804A1 (fr) 2006-12-22 2008-07-02 Novartis AG Préparation pharmaceutique comprenant un antagoniste de neurokinine
FR2938341A1 (fr) 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010063802A1 (fr) 2008-12-05 2010-06-10 Novartis Ag Cyclobutène-1,2-diones 3,4-disubstituées en tant qu'antagonistes de récepteur cxcr2
CN101530399B (zh) 2009-04-15 2011-01-26 江苏中兴药业有限公司 一种水飞蓟宾固体自乳化片
HUE049690T2 (hu) 2012-01-06 2020-10-28 Lundbeck La Jolla Research Center Inc Karbamátvegyületek és eljárások azok elõállítására és alkalmazására
JP6100883B2 (ja) 2012-03-19 2017-03-22 アビデ セラピューティクス，インク． カルバマート化合物、及びその製造並びに使用
WO2013159095A1 (fr) 2012-04-20 2013-10-24 Anderson Gaweco Modulateurs de ror et leurs utilisations
SG11201503365YA (en) 2012-11-02 2015-06-29 Vertex Pharma Pharmaceutical compositions for the treatment of cftr mediated diseases
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
CN105517547A (zh) 2013-07-03 2016-04-20 阿比德治疗公司 吡咯并吡咯氨基甲酸酯和相关的有机化合物、药物组合物及其医学用途
WO2015030854A1 (fr) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Formulation de dispersion orale d'un composé antiviral
CN103893258B (zh) 2013-12-05 2017-09-29 人福医药集团股份公司 含有广金钱草总黄酮的口服固体制剂及其应用
WO2015164160A1 (fr) 2014-04-21 2015-10-29 Merck Sharp & Dohme Corp. Sels pharmaceutiques d'un antagoniste des récepteurs de l'orexine
WO2015179559A2 (fr) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
JP2018513119A (ja) 2015-03-18 2018-05-24 アビデ セラピューティクス，インク． ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法
KR20180004263A (ko) 2015-05-11 2018-01-10 어바이드 테라퓨틱스, 인크. 염증 또는 신경병성 통증의 치료 방법
US10463753B2 (en) * 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
WO2018093950A1 (fr) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Formulations pharmaceutiques
HRP20211863T1 (hr) 2016-11-16 2022-03-04 H. Lundbeck A/S Formulacija za kontinuirano otpuštanje kolhicina i postupci priprave istog
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Also Published As

Publication number Publication date
RS62665B1 (sr) 2021-12-31
US20220235037A1 (en) 2022-07-28
IL266548A (en) 2019-07-31
TN2019000151A1 (en) 2020-10-05
EP3541807B1 (fr) 2021-09-29
CR20190242A (es) 2019-07-09
PL3541807T3 (pl) 2022-01-17
MY199386A (en) 2023-10-25
WO2018093953A1 (fr) 2018-05-24
CN115093382A (zh) 2022-09-23
JP2019537596A (ja) 2019-12-26
CN110291083A (zh) 2019-09-27
SMT202300494T1 (it) 2024-01-10
CL2019001340A1 (es) 2019-10-04
CA3043610A1 (fr) 2018-05-24
NZ753241A (en) 2021-06-25
MX2019005767A (es) 2019-12-05
SMT202100675T1 (it) 2022-01-10
EP3964503B1 (fr) 2023-11-08
PL3964503T3 (pl) 2024-04-02
AU2017361257B2 (en) 2022-02-10
RS65016B1 (sr) 2024-01-31
AU2017361257A1 (en) 2019-05-30
US11993588B2 (en) 2024-05-28
JP2022084717A (ja) 2022-06-07
KR20190077561A (ko) 2019-07-03
SI3541807T1 (sl) 2022-01-31
PT3541807T (pt) 2021-12-09
JOP20190109A1 (ar) 2019-05-09
HRP20231697T1 (hr) 2024-03-15
GEP20237559B (en) 2023-10-25
RU2019116689A (ru) 2020-12-17
KR102508739B1 (ko) 2023-03-09
CN110291083B (zh) 2022-06-17
NI201900053A (es) 2019-10-30
US20200190063A1 (en) 2020-06-18
JP7350117B2 (ja) 2023-09-25
MA58133B1 (fr) 2024-02-29
JOP20190109B1 (ar) 2022-09-15
JP7042548B2 (ja) 2022-03-28
RU2019116689A3 (fr) 2021-02-26
MX2022000249A (es) 2022-02-03
HRP20211863T1 (hr) 2022-03-04
EP3964503C0 (fr) 2023-11-08
HUE064559T2 (hu) 2024-03-28
EP3541807A4 (fr) 2020-04-22
DOP2019000120A (es) 2019-09-30
EP3964503A1 (fr) 2022-03-09
EA201991086A1 (ru) 2019-11-29
DK3541807T3 (da) 2021-12-06
ES2966939T3 (es) 2024-04-25
ECSP19035171A (es) 2019-05-31
MA46866B1 (fr) 2021-11-30
ES2900016T3 (es) 2022-03-15
HUE056973T2 (hu) 2022-04-28
BR112019010003A2 (pt) 2019-08-20
UA124585C2 (uk) 2021-10-13
PH12019501068A1 (en) 2019-08-19
CY1124870T1 (el) 2022-11-25
CO2019005045A2 (es) 2019-05-31
ZA201903093B (en) 2020-11-25
LT3541807T (lt) 2021-12-27
US11142517B2 (en) 2021-10-12
PE20191239A1 (es) 2019-09-16
EP3541807A1 (fr) 2019-09-25

Similar Documents

Publication Publication Date Title
MA46866A (fr) Une forme cristalline d'un inhibiteur de magl
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA44725A (fr) Formulations d'un inhibiteur de lsd1
EP3237402C0 (fr) Formes solides d'un inhibiteur d'ask 1
EP3357153A4 (fr) Circuit d'attaque pour actionneur capacitif à haute tension
MA42606A (fr) Sels d'un inhibiteur de lsd1
MA46652A (fr) Polythérapie pour l'inhibition de c3
MA47420A (fr) Composés inhibiteurs d'oga
MA46972A (fr) Forme polymorphe de sépiaptérine
EP3365344A4 (fr) Sel d'un inhibiteur d'egfr, forme cristalline correspondante et utilisations correspondantes
EP2969262A4 (fr) Compositions d'inhibition de corrosion
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
EP3277757A4 (fr) Compositions pour l'inhibition de corrosion
MA49006A (fr) Inhibiteurs d'ip6k
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
MA46567A (fr) Formes cristallines de l'éravacycline
EP3720268A4 (fr) Cultivar de stévia '16228013'
EP2970290A4 (fr) Forme cristalline d'un composé anxiolytique
MA48944A (fr) Forme cristalline de n-butyldéoxygalactonojirimycine
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
DK3343570T3 (da) 68GE/68GA-generator
EP3401365A4 (fr) Composition de rugosification d'une surface de résine
EP3422546A4 (fr) Circuit d'attaque de transistor
EP3395819A4 (fr) Forme cristalline de dérivé aminopyrane substitué